Cita APA (7a ed.)
Valerio, M. R., Sambataro, D., Martorana, F., Greco, M., Mesi, C., Gebbia, V., . . . Scandurra, G. (2026). Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review. Current Oncology, 33(4), 198-218.
Cita Chicago Style (17a ed.)
Valerio, Maria Rosaria, Daniela Sambataro, Federica Martorana, Martina Greco, Chiara Mesi, Vittorio Gebbia, Paolo Vigneri, y Giuseppa Scandurra. "Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review." Current Oncology 33, no. 4 (2026): 198-218.
Cita MLA (9a ed.)
Valerio, Maria Rosaria, et al. "Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review." Current Oncology, vol. 33, no. 4, 2026, pp. 198-218.
Precaución: Estas citas no son 100% exactas.